( -- Data from Serial Outpatient Infusion...)Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint,Health

MOUNTAIN VIEW, Calif. and NEW ORLEANS, March 25, 2007 /PRNewswire/ -- Scios Inc. announced today that an exploratory, 920-patient, Phase 2 study of nesiritide (NATRECOR(R)) showed a neutral effect on the primary endpoint, a composite of death and cardiorenal hospitalization at 12 weeks, and provides important renal and mortality safety data on nesiritide in patients with advanced chronic decompensated heart failure (CDHF) receiving serial outpatient infusions.

Data from the study, known as FUSION II (Follow-Up Serial InfusiOns of NATRECOR(R) in Advanced Heart Failure), were presented during a late-breaking clinical trial session at the of Cardiology's 56th Annual Scientific Session in New Orleans (presentation #402-9). Scios also announced that it plans to submit the safety data from this and other recent trials to the U.S. Food and Drug Administration (FDA).

NATRECOR(R) is the only FDA-approved intravenous treatment for patients with acutely decompensated congestive heart failure (ADHF) who have dyspnea (shortness of breath) at rest or with minimal activity.

FUSION II was designed to assess the long-term safety and outcomes at six months of once- or twice-weekly infusions of nesiritide compared to placebo in persistently symptomatic CDHF patients. All patients received ongoing intensive heart failure disease management, including optimization of standard heart failure medications and once or twice weekly outpatient clinic visits. Patients who participated in this trial had to have two prior recent hospitalizations, either NYHA class III or IV heart failure and had to have been out of the hospital for at least five days prior to enrollment in the trial.

The study demonstrated comparable renal and mortality
'"/>